Following SMC collaboration with NICE on TA971: remdesivir and tixagevimab plus cilgavimab for treating COVID-19:
remdesivir (Veklury®) is accepted for restricted use within NHSScotland.
Indication under review: treatment of COVID-19 in:
- adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).
- adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.
SMC restriction:
as an option for treating COVID-19 in hospitals in
- adults, only if they have a high risk of serious illness (risk factors as defined in section 5 of NICE’s technology appraisal of nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19).
- babies, children and young people, only if they:
- are aged 4 weeks to 17 years and weigh at least 3 kg, and have pneumonia and need supplemental oxygen, or
- weigh at least 40 kg and have a high risk of serious illness (risk factors as defined in section 5 of NICE’s technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19).
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
Download detailed advice252KB (PDF)
Medicine details
- Medicine name:
- remdesivir (Veklury)
- SMC ID:
- SMC2550
- Indication:
treatment of COVID-19 in:
-
-
adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).
-
adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.
-
-
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Infections
- Submission type
- Collaboration
- Status
- Restricted
- Date advice published
- 08 May 2024